We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.39 | 1.30% | 30.48 | 30.40 | 30.50 | 30.52 | 30.31 | 30.32 | 1,121,708 | 21:15:26 |
From May 2021 to May 2024
By Giulia Petroni
Roche Holding AG on Monday said that its phase 3 study on the use of Polivy in combination with chemotherapy regimen R-CHP for the treatment of diffuse large B-cell lymphoma met its primary endpoint.
The Swiss pharmaceutical giant said the trial showed the use of polatuzumab vedotin with rituximab plus cyclophosphamide, doxorubicin and prednisone significantly improves outcomes in patients with a previously untreated aggressive form of lymphoma compared with standard of care.
Roche said results of the study will be submitted to health authorities.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
August 09, 2021 02:43 ET (06:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
